Mosunetuzumab receives European Commission approval for the treatment of relapsed or refractory follicular lymphoma

On June 8, 2022, it was announced that the European Commission (EC) has granted approval for the use of mosunetuzumab, a CD20 × CD3 T-cell engaging bispecific antibody, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received ≥2 lines of systemic therapy. The approval is based on data obtained from the phase I/II GO29781 trial (NCT02500407),¹ previously reported on the Lymphoma Hub.

Efficacy¹

• 80% overall response rate
• 60% complete response rate
• Median duration of response was 22.8 months

Safety¹

• Overall, 39% of patients experienced any-grade cytokine release syndrome, with 14% being Grade 2.
• Most common adverse events were neutropenia, pyrexia, hypophosphatemia, and headache.
• Initial treatment dose was administered without mandatory hospitalization.